上海科技大学知识管理系统

提供一种抗新冠纳米抗体及其应用，所述纳米抗体包括CDR1、CDR2和CDR3；所述CDR1的氨基酸序列如SEQ ID NO : 1所示，所述CDR2的氨基酸序列如SEQ ID NO : 2所示，所述CDR3的氨基酸序列如SEQ ID NO : 3所示。提供一种融合蛋白，其由所述纳米抗体和Fc缀合而成；或由两个或多个纳米抗体缀合而成。所述应用为纳米抗体或融合蛋白在制备治疗新冠病毒的药物中的用途。所述纳米抗体对Omicron毒株具有中和潜力，具有分子量小、高结合活性，物化性质稳定和易于大规模生产及运输、储存等优点。其能结合RBDO，几乎完全抑制了RBDO与ACE2的结合，为双特异性甚至多特异性抗体、CAR分子的设计及组装奠定了基础。

Provided are an anti-SARS-Cov-2 nanobody and use thereof. The nanobody comprises CDR1, CDR2 and CDR3; the amino acid sequence of CDR1 is set forth in SEQ ID NO : 1, the amino acid sequence of CDR2 is set forth in SEQ ID NO : 2, and the amino acid sequence of CDR3 is set forth in SEQ ID NO : 3. Provided is a fusion protein, which is formed by the conjugation of the nanobody and an Fc, or by the conjugation of two or more nanobodies. The use refers to use of the nanobody or the fusion protein in the preparation of a drug for treating SARS-Cov-2. The nanobody has the potential to neutralize the Omicron strain, and has the advantages of small molecular weight, high binding activity, stable physical and chemical properties, ease of mass production, transport, storage, and the like. The nanobody can bind to RBDO and almost completely inhibits the binding of RBDO to ACE2, providing the foundations for the design and assembly of bispecific or even multispecific antibodies and CAR molecules.